Vigil Neuroscience Inc
NASDAQ:VIGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
US |
|
F
|
Firm Capital Property Trust
TSX:FCD.UN
|
CA |
|
Shenzhen Jiang & Associates Creative Design Co Ltd
SZSE:300668
|
CN |
|
Shanghai Baolijia Chemical Co Ltd
SZSE:301037
|
CN |
|
Arch Capital Group Ltd
NASDAQ:ACGL
|
BM |
|
S
|
Shri Dinesh Mills Ltd
BSE:503804
|
IN |
|
Aftermath Silver Ltd
XTSX:AAG
|
CA |
|
P
|
Plug Power Inc
XETRA:PLUN
|
US |
|
Crane NXT Co
NYSE:CXT
|
US |
|
Accel SAB de CV
BMV:ACCELSAB
|
MX |
|
U
|
Upsales Technology AB
STO:UPSALE
|
SE |
|
Ashok Leyland Ltd
BSE:500477
|
IN |
|
Genus PLC
LSE:GNS
|
UK |
|
T
|
Taier Heavy Industry Co Ltd
SZSE:002347
|
CN |
|
Parkland Corp
TSX:PKI
|
CA |
|
Saudi Arabian Amiantit Company SJSC
SAU:2160
|
SA |
|
9
|
908 Devices Inc.
NASDAQ:MASS
|
US |
|
Orpea SA
OTC:ORPEF
|
FR |
|
Yealink Network Technology Co Ltd
SZSE:300628
|
CN |
|
I
|
Impact Coatings AB (publ)
STO:IMPC
|
SE |
|
R
|
Rosbank PAO
MOEX:ROSB
|
RU |
|
AK Holdings Inc
KRX:006840
|
KR |
|
L'Oreal SA
PAR:OR
|
FR |
Vigil Neuroscience Inc
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2022-01-07. The firm is a microglia-focused therapeutics company. The company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company utilizes the tools of modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The firm's VGL101, a fully human monoclonal antibody targeting human TREM2 for the treatment of rare microgliopathies. The company is developing VGL101 for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, genetically defined, and fatal neurodegenerative disease caused by microglial dysfunction. The firm is also developing a novel small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.
Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. The company is headquartered in Cambridge, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2022-01-07. The firm is a microglia-focused therapeutics company. The company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. The company utilizes the tools of modern neuroscience drug development across multiple therapeutic modalities to deliver precision-based therapies to improve the lives of patients and their families. The firm's VGL101, a fully human monoclonal antibody targeting human TREM2 for the treatment of rare microgliopathies. The company is developing VGL101 for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare, genetically defined, and fatal neurodegenerative disease caused by microglial dysfunction. The firm is also developing a novel small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction.
